Linda is a Venture Partner at Atlas Venture. She most recently served as Chief Operating Officer and Chief Financial Officer for Mariana Oncology, a Novartis Company, as of May 2024. She brings extensive experience in operations, finance, capital markets, business development and transactions, strategy, investor relations, corporate communications and program management. She has raised nearly $1B in capital through venture, crossover rounds, IPOs and public equity financings over the past 10-plus years. Prior to Mariana Oncology, Linda served as Chief Financial Officer of Codiak BioSciences, CFO of Avalanche Biotechnologies, and Vice President of Finance, Business Operations, and Treasurer at bluebird bio. She previously held senior roles at Genzyme Corporation, including Vice President of Finance, Global Manufacturing and Operations, and Vice President of Finance, Genzyme Genetics and earlier in her career at Fidelity Investments, AstraZeneca, and Deloitte & Touche. Linda holds a B.S. in Accounting and Business Administration from the University of the Free State, Bloemfontein South Africa and an Honors Degree in Accounting and Business Administration. She currently serves on the Board of Directors of Arvinas, Autolus Therapeutics, Hemab Therapeutics, and Remix Therapeutics.